Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
October 03, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
August 08, 2019 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019
August 01, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Thursday, August 8 at 8:30 a.m. ET - Norwood, MA, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals to Host 2019 R&D Day in New York City
June 17, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- R&D Day to be live video webcasted on Friday, June 21st at 10:00 AM ET - Norwood, MA, June 17, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
June 12, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
May 28, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
New data from ongoing Phase 2 open-label extension of lenabasum in systemic sclerosis and open-label extension data in dermatomyositis studies to be presentedPresentation includes data from some...
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
May 09, 2019 07:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Continued progress made in four ongoing clinical studies as lenabasum advances towards 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis Second clinical candidate...
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 02, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company anticipates topline results of RESOLVE-1 study in the summer of 2020Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S.,...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
May 01, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
April 18, 2019 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 primary endpoint will now be aligned with that of previous Phase 2 studyACR CRISS is a composite index (composed of multiple outcomes including mRSS) and was secondary endpoint in current...